Anaveon AG
- Biotech or pharma, therapeutic R&D
Anaveon is on an exiting and fast paced journey: What began with a focus on immuno-oncology has rapidly evolved into a broader exploration of immune-driven disease. Our pipeline includes a bispecific IL-2 currently in Phase 1/2 trials and a bispecific IL-21 advancing through preclinical development—each designed to reverse immune exhaustion in the tumor microenvironment.
We're further pushing boundaries in immunology with our internally developed, depleting anti-PD-1 antibody—a novel approach for treating autoimmunity and supporting transplantation tolerance.
Further expanding our reach, we are licensing a bispecific anti-TSLP/anti-IL-11 antibody, now in Phase 1 studies. This asset targets the critical intersection of inflammation and fibrosis, and we’re developing it for asthma and other diseases where these pathways are key drivers of pathology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}